Brainsway Ltd
Brainsway Ltd (BWAY) designs and commercialised non-invasive neuromodulation systems using proprietary H-coil deep transcranial magnetic stimulation (dTMS). Its devices are used in clinical settings to treat psychiatric and neurological conditions such as major depressive disorder and obsessive–compulsive disorder, and the company pursues additional indications and geographic roll-out. Revenue sources include device sales, consumables and treatment sessions delivered through clinics or partner networks, alongside clinical partnerships and potential reimbursement gains. Key investment considerations include regulatory approvals, clinical evidence, reimbursement status and adoption by clinicians — factors that can influence near-term revenues and long-term growth. At the time of writing its market capitalisation is about $298.36m. Investors should note the typical risks for medical-device developers: clinical setbacks, regulatory delays, competition and variable reimbursement. This is general educational information, not personalised investment advice; suitability depends on an investor’s risk tolerance and objectives, and capital can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend purchasing Brainsway's stock, believing it will rise in value soon.
Financial Health
Brainsway Ltd is earning good revenue, maintaining a strong profit margin, and generating positive cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BWAY
Brain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketMind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical evidence momentum
New trial results and label expansions could widen patient access, though clinical outcomes and timing are uncertain and may affect uptake.
Technology differentiation
The proprietary H‑coil positions Brainsway in the neuromodulation space, supporting clinician interest — but competition and technological change remain risks.
Commercial & reimbursement
Growth depends on device sales, clinic adoption and payer coverage; improvements in reimbursement can boost revenues, yet coverage is variable by market.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
